Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Antenatal Anxiety and Dyadic Immune Risk (ADIR) Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 21, 2023
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 5, 2023
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 5, 2023
Giving Standardized Estradiol Therapy In Transgender Women to Research Interactions with HIV Therapy: the GET IT RIgHT Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 5, 2023
Rosuvastatin Efficacy and Safety for Cirrhosis in the United States (RESCU): A Double-Blind Randomized, Placebo-Controlled Phase 2 Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 11, 2023
A Real World Study of eCoin® for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 11, 2023
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 20, 2023
A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 21, 2023
Inventiva 337HNAS20011 (NATiV3): A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatoh
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 28, 2023
A Pragmatic Observational Study of Biometrics Collected by Wearable Technology in Patients with Liver Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: December 28, 2023